Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Natera, Inc. reported strong Q3 2025 topline growth alongside wider losses. Total revenues reached $592.2 million, up from $439.8 million a year ago, driven mainly by product revenues of $590.2 million. The company posted a net loss of $87.5 million, compared with a $31.6 million loss in Q3 2024, and a basic and diluted loss per share of $0.64 versus $0.26.
Operating expenses increased as Natera continued investing in its platform: research and development was $173.4 million and selling, general and administrative was $308.5 million. Revenue in the quarter included a $55.1 million net increase from changes in estimates for tests delivered in prior periods that were fully collected, which reduced loss per share by $0.40, and a $2.9 million revenue reduction from estimated insurance refunds, which increased loss per share by $0.02.
Liquidity remained solid. Cash, cash equivalents and restricted cash were $1.04 billion at September 30, 2025. Year‑to‑date operating cash flow was $141.4 million. The balance sheet shows $80.3 million outstanding on the Credit Line and $1.25 billion in stockholders’ equity. As context, common shares outstanding were 138,014,465 as of October 31, 2025.
Natera, Inc. furnished a Form 8‑K announcing results for its third quarter ended September 30, 2025, and provided a related investor presentation. The press release and presentation are included as Exhibits 99.1 and 99.2. The company states the information is furnished, not "filed," under the Exchange Act and is not incorporated into other filings unless expressly stated.
Natera, Inc. (NTRA) — Form 4 insider transaction
A reporting person who is a director and co‑founder disclosed open‑market sales of Natera common stock on 11/03/2025 under a Rule 10b5‑1 trading plan adopted on June 7, 2024. Two separate sales of 2,000 shares each were executed through trusts, for a total of 4,000 shares. One sale had a weighted average price of $200.1368 with trade prices ranging from $200.00 to $200.30; the other was reported at $200.00 per share.
Following the transactions, the filing lists 235,730 shares beneficially owned directly. The trusts are held for the benefit of their beneficiaries, and the reporting person disclaims beneficial ownership of those securities.
Natera, Inc. (NTRA) reported a Form 4 showing that its officer, President, Clinical Diagnostics, executed open‑market sales totaling 3,000 shares of common stock on 11/03/2025 under a Rule 10b5‑1 trading plan adopted on November 26, 2024.
The sales occurred in three tranches: 1,450 shares at a weighted average price of $198.026, 1,450 shares at $199.1023, and 100 shares at $199.74. Following these transactions, the reporting person beneficially owned 112,061 shares, held directly.
Natera (NTRA) reported an insider equity award. A director acquired 97 Restricted Stock Units on 10/31/2025, issued in lieu of a quarterly board retainer of $17,500. The RSUs were fully vested at issuance, and each RSU represents one share of common stock. Following this transaction, the director beneficially owns 5,316 shares directly.
Natera, Inc. disclosed a Form 4 reporting that a director acquired 128 shares through fully vested RSUs issued in lieu of a $23,125 quarterly board retainer on 10/31/2025. Each RSU represents one share of common stock.
After this transaction, the reporting person beneficially owned 6,143 shares held directly.
Natera (NTRA) disclosed a Form 4 for a board member showing an equity award on 10/31/2025. The director received 149 Restricted Stock Units (RSUs) issued in lieu of a $26,875 quarterly board retainer, and the RSUs were fully vested at grant.
After this transaction, the reporting person beneficially owned 6,839 shares directly and 1,224,787 shares indirectly through estate planning vehicles.
Natera, Inc. (NTRA) reported a routine insider transaction. A director filed a Form 4 showing an award of 93 Restricted Stock Units (RSUs) on 10/31/2025 in lieu of quarterly retainer fees of $16,875 for board service. The filing states the RSUs were fully vested at issuance, and each RSU represents the right to receive one share of common stock. Following this transaction, the reporting person beneficially owned 5,221 shares, held directly.
Natera, Inc. (NTRA) reported an insider equity award. On 10/31/2025, a director received 93 restricted stock units (RSUs) in lieu of a quarterly board retainer of $16,875. The filing states these RSUs were fully vested at issuance, and each RSU represents the right to receive one share of Natera common stock.
Following this transaction, the reporting person beneficially owned 18,359 shares, held directly.
Natera (NTRA) CEO and President reported multiple insider transactions on 11/03/2025. He exercised stock options for 2,084 shares at $13.01, 3,595 shares at $20.27, and 150,000 shares at $119.75, then sold 2,215 shares at a weighted average of $198.0293, 1,915 shares at $198.9619, and 156,573 shares at $199.9983. Following these trades, he beneficially owned 144,816 shares directly. The sales were made under a Rule 10b5-1 plan adopted on December 11, 2023 and amended on December 2, 2024.